OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Anti-BCMA novel therapies for multiple myeloma
Vincenzo Sammartano, Marta Franceschini, Sara Fredducci, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 1, pp. 169-181
Open Access | Times Cited: 17
Vincenzo Sammartano, Marta Franceschini, Sara Fredducci, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 1, pp. 169-181
Open Access | Times Cited: 17
Showing 17 citing articles:
Proteomic signatures improve risk prediction for common and rare diseases
Julia Carrasco-Zanini, Maik Pietzner, Jonathan Davitte, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2489-2498
Open Access | Times Cited: 14
Julia Carrasco-Zanini, Maik Pietzner, Jonathan Davitte, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2489-2498
Open Access | Times Cited: 14
In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?
Carlotta Mattioda, Claudia Voena, Gianluca Ciardelli, et al.
Cells (2025) Vol. 14, Iss. 1, pp. 38-38
Open Access
Carlotta Mattioda, Claudia Voena, Gianluca Ciardelli, et al.
Cells (2025) Vol. 14, Iss. 1, pp. 38-38
Open Access
Plasma Cell Myeloma and Related Disorders
Ruth M. de Tute, Andy C. Rawstron, Roger G. Owen, et al.
Cambridge University Press eBooks (2025), pp. 127-140
Closed Access
Ruth M. de Tute, Andy C. Rawstron, Roger G. Owen, et al.
Cambridge University Press eBooks (2025), pp. 127-140
Closed Access
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Emerging role of immune cells as drivers of pulmonary fibrosis
Steven E. Mutsaers, Tylah Miles, Cecilia M. Prêle, et al.
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108562-108562
Closed Access | Times Cited: 18
Steven E. Mutsaers, Tylah Miles, Cecilia M. Prêle, et al.
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108562-108562
Closed Access | Times Cited: 18
Proteomic prediction of common and rare diseases
Julia Carrasco-Zanini, Maik Pietzner, Jonathan Davitte, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 10
Julia Carrasco-Zanini, Maik Pietzner, Jonathan Davitte, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 10
Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Federico Riccardi, Carmela Tangredi, Michele Dal Bo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Federico Riccardi, Carmela Tangredi, Michele Dal Bo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
D Fric, Martin Štork, Ivanna Boichuk, et al.
European Journal Of Haematology (2024) Vol. 113, Iss. 6, pp. 810-816
Open Access | Times Cited: 2
D Fric, Martin Štork, Ivanna Boichuk, et al.
European Journal Of Haematology (2024) Vol. 113, Iss. 6, pp. 810-816
Open Access | Times Cited: 2
Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma
Xiangjun Shi, Yue Wu, Xingchen Yao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Xiangjun Shi, Yue Wu, Xingchen Yao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Recent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma
Fatemeh Sadat Shafiei, Saeid Abroun
Life Sciences (2024) Vol. 356, pp. 122989-122989
Closed Access | Times Cited: 1
Fatemeh Sadat Shafiei, Saeid Abroun
Life Sciences (2024) Vol. 356, pp. 122989-122989
Closed Access | Times Cited: 1
Effects of consolidation therapy with autologous hematopoietic stem cell transplantation after BCMA-CAR T-cell therapy on the survival of patients with relapsed or refractory multiple myeloma
Ziwei Zhou, Xuan Liu, Xuejun Zhang, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 11, pp. 1080.e1-1080.e11
Closed Access | Times Cited: 1
Ziwei Zhou, Xuan Liu, Xuejun Zhang, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 11, pp. 1080.e1-1080.e11
Closed Access | Times Cited: 1
Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells
Kamonlapat Supimon, Thanich Sangsuwannukul, Piriya Luangwattananun, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113480-113480
Open Access
Kamonlapat Supimon, Thanich Sangsuwannukul, Piriya Luangwattananun, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113480-113480
Open Access
Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
Alenka Djarmila Behsen, Toril Holien, Francesca Micci, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Alenka Djarmila Behsen, Toril Holien, Francesca Micci, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma
George Saied, Zachery Halford
Annals of Pharmacotherapy (2024)
Closed Access
George Saied, Zachery Halford
Annals of Pharmacotherapy (2024)
Closed Access
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615
Cindy Bandala, Donaciano Flores-Robles, Pavel Sierra-Martínez, et al.
Expert Opinion on Therapeutic Patents (2024)
Closed Access
Cindy Bandala, Donaciano Flores-Robles, Pavel Sierra-Martínez, et al.
Expert Opinion on Therapeutic Patents (2024)
Closed Access
Efficacy and Safety of Bispecific T-cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study
Suein Choi, Ja Min Byun, Sung‐Soo Park, et al.
Transplantation and Cellular Therapy (2024)
Closed Access
Suein Choi, Ja Min Byun, Sung‐Soo Park, et al.
Transplantation and Cellular Therapy (2024)
Closed Access
Finding the balance between immunoparesis recovery and multiple myeloma responses after autologous stem cell transplantation in the era of maintenance therapy and novel drugs
Alessandro Gozzetti, Irene Bernareggi, Vincenzo Sammartano
British Journal of Haematology (2023) Vol. 203, Iss. 5, pp. 706-707
Open Access
Alessandro Gozzetti, Irene Bernareggi, Vincenzo Sammartano
British Journal of Haematology (2023) Vol. 203, Iss. 5, pp. 706-707
Open Access
